Home » Stocks » Voyager Therapeutics

Voyager Therapeutics, Inc. (VYGR)

Stock Price: $11.18 USD -0.01 (-0.09%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $11.00 -0.18 (-1.61%) Aug 10, 4:21 PM

Stock Price Chart

Key Info

Market Cap 415.79M
Revenue (ttm) 117.26M
Net Income (ttm) -40.69M
Shares Out 37.16M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $11.18
Previous Close $11.19
Change ($) -0.01
Change (%) -0.09%
Day's Open 11.70
Day's Range 11.13 - 11.71
Day's Volume 296,745
52-Week Range 6.26 - 23.50

More Stats

Market Cap 415.79M
Enterprise Value 164.86M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 37.16M
Float 23.12M
EPS (basic) -1.11
EPS (diluted) -1.11
FCF / Share -3.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.14M
Short Ratio 8.18
Short % of Float 10.84%
Beta 1.82
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.55
PB Ratio 5.12
Revenue 117.26M
Operating Income -46.82M
Net Income -40.69M
Free Cash Flow -113.24M
Net Cash 250.93M
Net Cash / Share 6.75
Gross Margin -13.09%
Operating Margin -39.93%
Profit Margin -34.70%
FCF Margin -96.57%
ROA -7.97%
ROE -45.10%
ROIC -22.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 10
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(107.96% upside)
Current: $11.18
Target: 23.25
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth1270.14%-24.82%-28.73%-17.96%--
Gross Profit1047.6210.1414.2217.33-
Operating Income-51.68-91.10-71.86-41.30-20.25-14.37
Net Income-43.60-88.29-70.70-40.19-29.67-16.32
Shares Outstanding35.9032.0726.8025.304.190.64
Earnings Per Share-1.21-2.75-2.64-1.59-9.14-27.83
Operating Cash Flow48.67-15.89-61.35-42.4841.30-11.92
Capital Expenditures-7.55-4.31-3.99-5.03-1.03-2.99
Free Cash Flow41.12-20.19-65.34-47.5140.27-14.91
Cash & Equivalents2821561691741947.04
Net Cash / Debt2821561691741947.04
Book Value99.5146.45134136169-20.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Voyager Therapeutics, Inc.
Country United States
Employees 185
CEO Steven Marc Paul / G. Andre Turenne

Stock Information

Ticker Symbol VYGR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VYGR
IPO Date November 11, 2015


Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with AbbVie Inc.; the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.